Michael Tarantino, MD
Pediatric Hematology-Oncology · Peoria, ILNPI 1396731063
Payments from drug & device makers
Across 517 payments — averaging $1419.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$137K
- Sanofi$116K
- Sanofi US Services Inc.$64K
- Amgen$48K
- Swedish Orphan Biovitrum AB$46K
- Dova Pharmaceuticals$40K
- plus $283K from 23 others
Across 3 payments — averaging $7439.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$22K
- Eli Lilly$183
What the payments were for
- Consulting fees$262,47748%
- Speaking & faculty fees$222,26841%
- Travel & lodging$51,7359%
- Food & beverage$10,7232%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 123 | $137,176 |
| Sanofi | 59 | $116,169 |
| Sanofi US Services Inc. | 15 | $63,826 |
| Amgen | 32 | $47,742 |
| Swedish Orphan Biovitrum AB | 8 | $45,620 |
| Dova Pharmaceuticals | 22 | $40,422 |
| Shire North American Group Inc | 51 | $40,099 |
| Genentech USA, Inc. | 39 | $38,009 |
| Octapharma USA, Inc. | 14 | $33,367 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $29,509 |
| Biomarin Pharmaceutical Inc. | 19 | $23,195 |
| Spark Therapeutics, Inc. | 24 | $23,179 |
| Pfizer | 11 | $19,035 |
| Grifols USA, LLC | 21 | $18,740 |
| UCB SA | 6 | $11,341 |
| Novartis | 7 | $10,422 |
| Kedrion Biopharma, Inc. | 15 | $8,711 |
| Novo Nordisk | 4 | $7,579 |
| F. Hoffmann-la Roche AG | 3 | $4,706 |
| CSL Behring | 7 | $4,651 |
| OPKO Pharmaceuticals, LLC | 1 | $3,056 |
| Novo Nordisk AS | 2 | $2,944 |
| Principia Biopharma Inc. | 1 | $1,500 |
| Argenx US, Inc. | 1 | $1,250 |
| Medexus Pharma, Inc. | 1 | $800 |
| Bioverativ Therapeutics Inc. | 1 | $500 |
| Bio Products Laboratory USA, Inc. | 3 | $149 |
| Boston Scientific | 1 | $94 |
| Grifols Shared Services North America, Inc. | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DOPTELET$148,228
- WAYRILZ$68,431
- HEMLIBRA$41,822
- Nplate$40,235
- ADVATE$25,929
- Thrombate III$18,489
- OBIZUR$15,432
- ADYNOVATE$13,805
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$13,659
- ADLYXIN$10,338
- BENEFIX$7,500
- PROMACTA$7,341
- RYPLAZIM$6,000
- HEMGENIX$4,440
- Idelvion$4,440
- Coagadex$2,367
- FEIBA$1,500
- VYVGART$1,250
- IXINITY$800
- NUWIQ$266
How this compares
$733,828 in reported general payments places this provider in the 90th percentile of 78 pediatric hematology-oncology providers in Illinois.
See all pediatric hematology-oncology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 321 | $239,532 |
| XareltoRivaroxaban | 94 | $65,824 |
| Enoxaparin Sodium | 20 | $4,839 |
| Warfarin Sodium | 375 | $3,046 |
| Meloxicam | 33 | $201 |
| Folic Acid | 18 | $103 |
| JantovenWarfarin Sodium | 26 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19,035 | $239,532321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 78 pediatric hematology-oncology providers in Illinois.
Other pediatric hematology-oncology in Peoria
- Pedro DealarconPeoria$469K
- Rueben AntonyPeoria$106K
- Mary RossPeoria$89K
- Prerna KumarPeoria$10K
- Surabhi BatraPeoria$1K
- Kay SavingPeoria$229
- Alexis ThompsonChicago$6.2M
- Stewart GoldmanChicago$2.2M
- Sonali ChaudhuryChicago$2.1M
- Robert LiemChicago$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.